Ankle Injuries
1
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Paragon 28CO - Englewood
3 programsGrappler Interference Screw SystemN/A1 trial
Grappler® Interference Screw SystemN/A1 trial
Monster Screw SystemN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
PfizerTopical IBU twice daily
Paragon 28Monster Screw System
Paragon 28Grappler Interference Screw System
Paragon 28Grappler® Interference Screw System
Clinical Trials (4)
Total enrollment: 455 patients across 4 trials
5% Topical Ibuprofen (IBU) for Ankle Sprain
Start: Nov 2013Est. completion: Feb 2015304 patients
Phase 3Completed
Monster Screw System Post-Market Clinical Follow-Up Study
Start: Jan 2022Est. completion: Sep 202282 patients
N/ACompleted
Grappler Interference Screw Post-Market Collection of Patient Reported Outcome Measures
Start: Jan 2022Est. completion: Apr 202219 patients
N/ACompleted
Grappler® Interference Screw Post-Market Clinical Follow-Up Study
Start: Apr 2021Est. completion: Mar 202250 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.